- Home
- SABR vs ANNX Comparison
SABR vs ANNX Comparison
Compare SABR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | ANNX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.3M | 812.7M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SABR | ANNX |
|---|---|---|
| Price | $1.53 | $5.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 5.6M | 1.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $3,866,956,000.00 | N/A |
| Revenue This Year | $7.51 | N/A |
| Revenue Next Year | $3.46 | $16,320.74 |
| P/E Ratio | $77.75 | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $1.85 |
| 52 Week High | $3.46 | $7.18 |
Technical Indicators
Market Signals| Indicator | SABR | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 44.52 |
| Support Level | $1.49 | $5.28 |
| Resistance Level | $1.61 | $5.61 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 6.16 | 40.34 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.